Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Bridging Therapy in High-Risk B-ALL
NCT04556084Phase 2Terminated
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL). Started Jan 2021; status: terminated.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04556084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556084.